慢性自发性荨麻疹药物治疗的研究进展  

Research Progress of Drug Therapy for Chronic Spontaneous Urticaria

作　　者：曹凯丽 朱雅琳[1] CAO Kaili;ZHU Yalin(Department of Dermatology,the First Affiliated Hospital of Xinjiang Medical University,Urumqi 830000,China)

机构地区：[1]新疆医科大学第一附属医院皮肤科,乌鲁木齐830000

出　　处：《医学综述》2024年第24期3007-3011,共5页Medical Recapitulate

摘　　要：慢性自发性荨麻疹(CSU)是临床常见的免疫相关性皮肤病,最常见的临床表现为风团和皮肤瘙痒。该病病因及发病机制较为复杂,皮肤肥大细胞病理性激活和脱颗粒是其关键因素。目前,CSU的标准治疗方法为第二代抗组胺药和奥马珠单抗治疗。然而,许多患者对这些药物具有抵抗性和耐药性。对于这些难治患者,联合雷公藤苷、环孢菌素等治疗已在一些病例中成功使用。此外,各种其他生物制剂和新兴药物已成为该疾病的潜在治疗方法。目前有许多药物正在进行随机临床试验研究,未来将会出现更多的药物用于治疗该病。Chronic spontaneous urticaria(CSU)is a common immune-related skin disease in clinical practice,and the most common clinical manifestations are wheals and pruritus.The etiology and pathogenesis of the disease are complex,and pathological activation and degranulation of skin mast cells are the key factors.Currently,the standard treatment for CSU is second-generation antihistamines and omalizumab.However,many patients are resistant and tolerant to these drugs.For these refractory patients,the combination of triptolide and cyclosporine has been successfully used in some cases.In addition,a variety of other biologics and emerging drugs have become potential treatments for the disease.There are a number of drugs currently being studied in randomized clinical trials,and more drugs will be used to treat the disease in the future.

关 键 词：慢性自发性荨麻疹 抗组胺药物 奥马珠单抗 

分 类 号：R758.24[医药卫生—皮肤病学与性病学]